Leveraging Imaging RWD to Develop a Novel Technology for Optimizing PSMA Theranostics in Prostate Cancer
June 15 @1pm ET.
Recent approval of prostate specific membrane antigen (PSMA) theranostic is rapidly changing the standard of care for diagnosing, staging and managing prostate cancer.
Key challenges exist with theranostics such as identifying which patients would benefit from treatment, optimizing the therapeutic dose, monitoring and predicting treatment response, and preventing toxicity.
Key take aways from the webinar
- How to define, identify and recruit the mCRPC patient cohort required to assess PSMA’s role in prostate cancer
- Leveraging Imaging RWD to assess the mCRPC PET Scan
- Learning about a new technology, TRAQinform IQ, that will use standard-of-care imaging to support clinical decisions around the use of theranostics
- Understanding how TRAQinform IQ technology will be usead for theranostics treatment optimization